Por: RTTNews Health November 29, 2023
Biopharmaceutical company AbbVie, Inc. () announced Wednesday topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal growth factor receptor (EGFR) wild type, advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC). The trial demonstrated compelling clinical benefits across key endpoints.The results demonstrated a compelling... + full article
Portland Press Herald USA World December 01, 2023
AbbVie will pay around $10 billion to add a potential blockbuster cancer treatment as cheaper versions of the drugmaker’s all-time best seller, Humira, cut into sales. But company leaders cautioned Thursday that a return on the deal they announced for drug developer ImmunoGen... + más
Every NBA finals matchup and winner | ESPN
How a Drug Company Made $114 Billion by Gaming the U.S. Patent System | The New York Times
RTTNews USA Health September 29, 2023
AbbVie () announced Friday data from its Phase 3 CANOVA study evaluating the safety and efficacy of venetoclax (VENCLEXTA®/ VENCLYXTO®) plus dexamethasone (VenDex) for patients with t(11;14)-positive relapsed or refractory (R/R) multiple myeloma who have received two or more... + más
AbbVie Posts an Earnings Beat but Forecast Misses as Competition Intensifies | MarketWatch
RTTNews USA Health September 22, 2023
Merck & Co Inc. (), known as MSD outside of the U.S. and Canada, announced Friday positive topline results from the Phase 3 KEYNOTE-A39 trial, which was conducted in collaboration with Seagen Inc. () and Astellas Pharma Inc. (ALPMY.PK,).The trial evaluated KEYTRUDA, Merck's... + más
Column: Merck says it's being 'coerced' into negotiating its drug prices with Medicare. That's nonsense | Los Angeles Times
Merck sues U.S., calling Biden move to cut drug prices ‘extortion’ | Portland Press Herald
MarketWatch USA Business February 09, 2023
International sales of Humira fell 26.5% from last year as the company lost patent protection in Europe and . However, revenue for the drug that treats Crohn’s disease grew 4.6% globally in the quarter to $5.58 billion, which was slightly above analysts’ estimates. said... + más
Cigna’s PBM Express Scripts Latest To Put Less Pricey Biosimilars Of Abbvie’s Humira On Preferred Drug List | Forbes
The New York Times USA Business January 28, 2023
In 2016, a blockbuster drug called Humira was poised to become a lot less valuable.The key patent on the best-selling anti-inflammatory medication, used to treat conditions like arthritis, was expiring at the end of the year. Regulators had blessed a rival version of the drug,... + más
Will More Women Patent Attorneys Lead To More Women Inventors? | Forbes
Samsung Beats IBM, Apple, Intel, Google For 2022 Patent Crown; 56% Of U.S. Patents Go To Foreign Firms | Forbes
ABC News USA Life January 06, 2023
The 30 women who will compete for ' heart on The Bachelor season 27 have been revealed.The 26-year-old tech executive from Anaheim Hills, California, will meet a group that includes four nurses, along with a few other medical professionals, a nanny from Vienna, a dancer and... + más
When is The Bachelor Season 27 out? Release date, contestants plus more | Newsweek
All the stars on 'Bachelor in Paradise' cast and when you last saw them | Newsweek
Forbes USA Tech December 05, 2022
Cigna’s pharmacy benefit manager Express Scripts will put “multiple biosimilar versions of Abbvie’s ... [+] expensive rheumatoid arthritis drug Humira in the “same position as the brand” on the PBM’s as a formulary in 2023. AbbVie's signature drug Humira is... + más
Cigna received millions of Medicare dollars based on invalid diagnoses, lawsuit claims | ABC News
How To Get Away With Corporate Murder: Unbundling And Disrupting Pharmacy Benefit Managers (Part 2) | Forbes
About iurex | Privacy Policy | Disclaimer |